-
Tytuł:
-
Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
-
Autorzy:
-
Zhou, Yufan
Yan, Chong
Gu, Xinyu
Zhou, Lei
Lu, Jun
Zhu, Wenhua
Huan, Xiao
Luo, Sushan
Zhong, Huahua
Lin, Jie
Lu, Jiahong
Zhao, Chongbo
Xi, Jianying
-
Temat:
-
AUTOANTIBODIES
RESEARCH
MYASTHENIA gravis
CHOLINERGIC receptors
RESEARCH methodology
MEDICAL cooperation
EVALUATION research
TREATMENT effectiveness
COMPARATIVE studies
IMMUNOLOGICAL adjuvants
TRANSFERASES
RESEARCH funding
-
Źródło:
-
Muscle & Nerve; Jun2021, Vol. 63 Issue 6, p824-830, 7p
-
Introduction/aims: The study aims to investigate the short-term efficacy of low-dose rituximab and its effect on immunological biomarker levels in myasthenia gravis (MG) patients with antibodies against muscle-specific tyrosine kinase (MuSK-MG).Methods: Twelve MuSK-MG patients were enrolled in this prospective, open-label, self-controlled pilot study. Clinical severity was evaluated at baseline and 6 mo after a single rituximab treatment (600 mg). B lymphocyte subtypes, MuSK antibody titers, together with levels of immunoglobulins, serum B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), soluble CD40L, and four exosomal microRNAs were evaluated. A correlation matrix to reveal pairwise relationships among above variables was also generated.Results: The single rituximab treatment significantly lowered the clinical severity scores and reduced daily dosage of prednisone (P = .032) at 6 mo. MuSK antibody titers decreased (P = .035) without significant changes in immunoglobulin levels. Serum BAFF level increased (P = .010), which negatively correlated with the percentages of B cells in lymphocytes as well as clinical severity. Additionally, serum exosomal miR-151a-3p showed a reduction of 28.1% (P = .031).Discussion: We confirmed the clinical efficacy of low-dose rituximab in MuSK-MG, accompanied by a decrease in MuSK antibody titers and an increase in serum BAFF. Serum BAFF levels negatively correlated with B-cell counts as well as clinical severity. [ABSTRACT FROM AUTHOR]
Copyright of Muscle & Nerve is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)